Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The emergence of antibiotic resistance in a wide variety of important pathogens of humans presents a worldwide threat to public health. This paper describes recent work on the use of mathematical models of the emergence and spread of resistance bacteria, on scales ranging from within the patient, in hospitals and within communities of people. Model development starts within the treated patient, and pharmacokinetic and pharmacodynamic principles are melded within a framework that mirrors the interaction between bacterial population growth, drug treatment and the immunological responses targeted at the pathogen. The model helps identify areas in which more precise information is needed, particularly in the context of how drugs influence pathogen birth and death rates (pharmacodynamics). The next area addressed is the spread of multiply drug–resistant bacteria in hospital settings. Models of the transmission dynamics of the pathogen provide a framework for assessing the relative merits of different forms of intervention, and provide criteria for control or eradication. The model is applied to the spread of Vancomycin–resistant enterococci in an intensive care setting. This model framework is generalized to consider the spread of resistant organisms between hospitals. The model framework allows for heterogeneity in hospital size and highlights the importance of large hospitals in the maintenance of resistant organisms within a defined country. The spread of methicillin resistant Staphylococcus aureus(MRSA) in England and Wales provides a template for model construction and analysis. The final section addresses the emergence and spread of resistant organisms in communities of people and the dependence on the intensity of selection as measured by the volume or rate of drug use. Model output is fitted to data for Finland and Iceland and conclusions drawn concerning the key factors determining the rate of spread and decay once drug pressure is relaxed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
Infectious Diseases of Humans: Dynamics and Control
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-2-174_4 · Cited by 7,746
Vetterling, W. T., Teukolsky, S. A., Press, W. H., & Flannery, B. P. (1988) · Cited by 7,701
Infectious Diseases of Humans: Dynamics and Control
Anderson, R. M., & May, R. M. (1991) · doi:10.1093/oso/9780198545996.001.0001 · Cited by 6,179
Self-citationRapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,267 · cited 1×
“The use of mathematical models for the analysis of viral infections such as HIV has resulted in considerable advances in our understanding of both disease progression and the impact of drug therapy (Ho et al. 1995;Wei et al. 1995; Bonhoe¡er et al. 1996; Austin et al. 1998b).”
MethodViral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,260
Clinical pharmacokinetics; concepts and applications
(1989) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(89)90348-0 · Cited by 2,223
Hall, A. J. (1992) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(92)90276-i · Cited by 2,131
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333 · cited 2×
“Reports of MRSA strains with reduced susceptibility to vancomycin (Hiramatsu et al. 1997; Tabaqchali 1997), suggest that unless there is a return to conventional practices of infection control, with its emphasis on reduced transmission, antibiotic therapy may not be possible in the near future for some hospital acquir…”
BackgroundSeppälä, H., Klaukka, T., Vuopio-Varkila, J., Muotiala, A., Helenius, H., Lager, K., & Huovinen, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708143370701 · Cited by 1,206
Cited by
Antibiotic resistance and its cost: is it possible to reverse resistance?
Andersson, D. I., & Hughes, D. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2319 · Cited by 2,294
White, N. J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421682 · Cited by 1,248
Wellington, E. M., Boxall, A. B., Cross, P., Feil, E. J., Gaze, W. H., Hawkey, P. M., Johnson-Rollings, A. S., Jones, D. L., Lee, N. M., Otten, W., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70317-1 · Cited by 1,122
The biological cost of antibiotic resistance
Andersson, D. I., & Levin, B. R. (1999) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(99)00005-3 · Cited by 867
Bacterial Resistance: Origins, Epidemiology, and Impact
Livermore, D. M. (2003) · Clinical Infectious Diseases · doi:10.1086/344654 · Cited by 586
Antimicrobial Use and Antimicrobial Resistance: A Population Perspective
Lipsitch, M., & Samore, M. H. (2002) · Emerging Infectious Diseases · doi:10.3201/eid0804.010312 · Cited by 497
Persistence of antibiotic resistance in bacterial populations
Andersson, D. I., & Hughes, D. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00289.x · Cited by 435
Of Pseudomonas, porins, pumps and carbapenems
Livermore, D. M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.3.247 · Cited by 391
WHO Guidelines for the treatment of malaria
Kunte, R., & Kunwar, R. (2011) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(16)30022-3 · Cited by 341
Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Nielsen, E. I., & Friberg, L. E. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005769 · Cited by 332
Karageorgopoulos, D. E., Wang, R., Yu, X.-H., & Falagas, M. E. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr466 · Cited by 228
Antibacterials dispensed in the community comprise 85%–95% of total human antibacterial consumption
Duffy, E., Ritchie, S., Metcalfe, S., Van Bakel, B., & Thomas, M. G. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12610 · Cited by 155
Sony, M., Sumithra, T. G., Anusree, V. N., Amala, P. V., Reshma, K. J., Alex, S., & Sanil, N. K. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.736608 · Cited by 106
Wang, L., & Ruan, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-00261-1 · Cited by 63
Does Antibiotic Resistance Evolve in Hospitals?
Seigal, A., Mira, P., Sturmfels, B., & Barlow, M. (2017) · Bulletin of Mathematical Biology · doi:10.1007/s11538-016-0232-7 · Cited by 18
Metadata
- Authors
- Austin, D. J., & Anderson, R. M.
- Venue
- Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences
- Publisher
- The Royal Society
- Published
- 1999-04-29
- Volume
- 354
- Issue
- 1384
- Pages
- 721-738
- ISSN
- 0962-8436 (ISSN-L)
- 1471-2970
- OpenAlex
- W2036519794
- Cited by
- 195
- References
- 54
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.